Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report
Free accessResearch articleFirst published online November, 2016
Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report
Currently pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Because of its late manifestation and consequent dismal prognosis, there is an urgent need to develop highly sensitive and specific marker. Neutrophil Gelatinase-Associated Lipocalin (NGAL) recently emerged as a protein playing an important role in carcinogenesis of various neoplasms.
OBJECTIVE:
Our aim was to assess the potential of urine and bile concentration of NGAL in differentiating pancreatic adenocarcinoma from chronic pancreatitis.
METHODS:
Forty-two patients operated on due to pancreatobiliary lesions were enrolled in this study. All enrolled patients had eGFR within reference range. Levels of CEA, CA 125 and Ca19-9 were assessed using standard laboratory protocols. A sample of urine was collected prior to the surgery. Intraoperatively a 5 ml sample of bile was collected directly from the common bile duct. Bile and urine levels of NGAL were measured using a ELISA kit. After standard pathological examination of specimens obtained during surgery, patients were divided into 2 groups: 21 patients with pancreatic adenocarcinoma and 15 patients with focal chronic pancreatitis.
RESULTS:
NGAL concentration in bile in patients with PDAC vs CP was 75.72 ± 16.05 ng/mL vs 62.62 ± 18.6 ng/mL respectively (p= 0,011). NGAL concentration in urine was 43.26 ± 21.21 ng/mL vs 17.96 ± 14.58 ng/mL (p= 0.002) respectively. In order to compare these markers with routinely used ones, ROC curve was built for Ca125 to establish cutoff point and in case of CA19-9 clinically used cutoff (≥ 37U/mL) was applied. Sensitivity and specificity for NGALurine with cutoff value of 27 ng/mL was 80.95% and 80% respectively, while these values for NGALbile were 71.43% and 80% respectively. Ca19-9 measured in plasma with clinically used cutoff value had sensitivity of 71.43% and specificity of 73.33%. Sensitivity and specificity for Ca 125 measured in plasma with cutoff value of 13 U/mL were 85.71% and 66.67% respectively.
CONCLUSIONS:
In conclusion, NGAL in urine and bile are remarkably accurate in differentiating pancreatic mass due to chronic pancreatitis from pancreatic adenocarcinoma. Therefore, NGAL concentrations in bile and urine should be further investigated in order to assess their usefulness in early pancreatic adenocarcinoma diagnosis.
SiegelRL, MillerKD, JemalA: Cancer statistics, 2015. CA Cancer J Clin2015, 65.
2.
AlexakisN, HalloranC, RaratyM, GhanehP, SuttonR, NeoptolemosJP: Current standards of surgery for pancreatic cancer. Br J Surg2004, 91: 1410-1427.
3.
NiteckiSS, SarrMG, ColbyTV, van HeerdenJA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?Ann Surg1995, 221.
4.
YeoCJ, CameronJL, SohnTA, LillemoeKD, PittHA, TalaminiMA et al.: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg1997, 226: 248-57; discussion 257-260.
5.
SchmidtCM, PowellES, YiannoutsosCT, HowardTJ, WiebkeEA, WiesenauerCA et al.: Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg2004, 139: 718-25; discussion 725-727.
6.
SmithCD, BehrnsKE, van HeerdenJA, SarrMG: Radical pancreatoduodenectomy for misdiagnosed pancreatic mass. Br J Surg1994, 81: 585-589.
7.
CameronJL, PittHA, YeoCJ, LillemoeKD, KaufmanHS, ColemanJ: One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg1993, 217: 430-5; discussion 435-438.
8.
BoggiU, AmoreseG, VistoliF, CanigliaF, De LioN, PerroneV et al.: Laparoscopic pancreaticoduodenectomy: a systematic literature review. Surg Endosc2015, 29.
9.
FrampasE, MorlaO, RegenetN, EugeneT, DupasB, MeuretteG: A solid pancreatic mass: tumour or inflammation?Diagn Interv Imaging2013, 94: 741-755.
10.
DuttaAK, ChackoA: Head mass in chronic pancreatitis: Inflammatory or malignant. World J Gastrointest Endosc2015, 7: 258-264.
11.
ChakrabortyS, KaurS, GuhaS, BatraSK: The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta2012, 1826: 129-169.
12.
CowlandJB, BorregaardN: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics1997, 45.
13.
FlowerDR: The lipocalin protein family: structure and function. Biochem J1996, 318(Pt 1).
14.
YangJ, GoetzD, LiJY, WangW, MoriK, SetlikD, DuT, Erdjument-BromageH, TempstP, StrongR, BaraschJ: An iron delivery pathway mediated by a lipocalin. Mol Cell2002, 10: 1045-1056.
15.
YangJ, BlumA, NovakT, LevinsonR, LaiE, BaraschJ: An epithelial precursor is regulated by the ureteric bud and by the renal stroma. Dev Biol2002, 246.
MallbrisL, O'BrienKP, HulthenA, SandstedtB, CowlandJB, BorregaardN, Stahle-BackdahlM: Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin. Exp Dermatol2002, 11: 584-591.
18.
DingL, HanawaH, OtaY, HasegawaG, HaoK, AsamiF, WatanabeR, YoshidaT, TobaK, YoshidaK, OguraM, KodamaM, AizawaY: Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J2010, 74: 523-530.
19.
CowlandJB, SorensenOE, SehestedM, BorregaardN: Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol2003, 171: 6630-6639.
20.
DevireddyLR, GazinC, ZhuX, GreenMR: A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell2005, 123: 1293-1305.
21.
WangY, ZengT: Neutrophil gelatinase-associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta-analysis. Biomed Rep2013, 1.
22.
WangH-J, HeX-J, MaY-Y, JiangX-T, XiaY-J, YeZ-Y, ZhaoZ-S, TaoH-Q: Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken)2010, 293: 1855-1863.
LimR, AhmedN, BorregaardN, RileyC, WafaiR, ThompsonEW, QuinnMA, RiceGE: Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer2007, 120: 2426-2434.
25.
KrysanK, CuiX, GardnerBK, ReckampKL, WangX, HongL et al.: Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res2013, 5: 481-496.
26.
ShinrikiS, JonoH, UedaM, ObayashiK, NakamuraT, OtaK et al.: Stromal expression of neutrophil gelatinase-associated lipocalin correlates with poor differentiation and adverse prognosis in oral squamous cell carcinoma. Histopathology2014, 64: 356-364.
27.
GoonetillekeKS, SiriwardenaAK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol2007, 33: 266-270.
28.
MarrelliD, CarusoS, PedrazzaniC, NeriA, FernandesE, MariniM et al.: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg2009, 198: 333-339.
29.
ParraJL, KaplanS, BarkinJS: Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci2005, 50: 694-695.
30.
HuangZ, LiuF: Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol2014, 35: 7459-7465.
31.
HaglundC, LundinJ, KuuselaP, RobertsPJ: CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer1994, 70: 487-492.
32.
WuX, LuXH, XuT, QianJM, ZhaoP, GuoXZ et al.: Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis2006, 7: 170-174.
33.
JiangJ-T, WuC-P, DengH-F, LuM-Y, WuJ, ZhangH-Y et al.: Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol2004, 10: 1675-1677.
34.
OzkanH, KayaM, CengizA: Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology2003, 50: 1669-1674.
35.
JiangX-T, TaoH-Q, ZouS-C: Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int2004, 3: 464-468.
36.
LiaoQ, ZhaoY-P, YangY-C, LiL-J, LongX, HanS-M: Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int2007, 6: 641-645.
37.
HaridasD, ChakrabortyS, PonnusamyMP, LakshmananI, RachaganiS, CruzE et al.: Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One2011, 6.
38.
LuoG, XiaoZ, LongJ, LiuZ, LiuL, LiuC et al.: CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg2013, 17: 2092-2098.
39.
ChanA, PrassasI, DimitromanolakisA, BrandRE, SerraS, DiamandisEP, BlasutigIM: Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res2014, 20: 5787-5795.
40.
ChenT, ZhangM-G, XuH-X, WangW-Q, LiuL, YuX-J: Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore)2015, 94.
HanH, BearssDJ, BrowneLW, CalaluceR, NagleRB, Von HoffDD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res2002, 62: 2890-2896.
43.
MoniauxN, ChakrabortyS, YalnizM, GonzalezJ, ShostromVK, StandopJ et al.: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer2008, 98: 1540-1547.
44.
KaurS, ChakrabortyS, BaineMJ, MallyaK, SmithLM, SassonA, BrandR, GuhaS, JainM, WittelU, SinghSK, BatraSK: Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One2013, 8.
45.
BudzynskaA, Nowakowska-DulawaE, MarekT, BoldysH, NowakA, HartlebM: Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin. J Physiol Pharmacol2013, 64: 109-114.
46.
ZabronAA, Horneffer-van der SluisVM, WadsworthCA, LairdF, GierulaM, ThillainayagamAV et al.: Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol2011, 106: 1711-1717.
47.
ErkanM, Reiser-ErkanC, MichalskiCW, DeuckerS, SauliunaiteD, StreitS et al.: Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia2009, 11.
48.
KlöppelG, AdsayNV: Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med2009, 133: 382-387.
49.
BolignanoD, LacquanitiA, CoppolinoG, CampoS, ArenaA, BuemiM: Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res2008, 31: 255-258.
